Latest Sense Stories
Scientists have found out how people can taste the bubbly sensation from carbonated beverages.The answer appears to lie in an enzyme on the surface of sour-sensing cells in taste buds, researchers reported in the journal Science.Researchers at National Institutes of Health's National Institute of Dental and Craniofacial Research (NIDCR) and colleagues from the Howard Hughes Medical Institute at the University of California, San Diego (UCSD) used mice in their study.Mice have a similar sense...
In 1767, chemist Joseph Priestley stood in his laboratory one day with an idea to help English mariners stay healthy on long ocean voyages. He infused water with carbon dioxide to create an effervescent liquid that mimicked the finest mineral waters consumed at European health spas. Priestley's man-made tonic, which he urged his benefactors to test aboard His Majesty's ships, never prevented a scurvy outbreak. But, as the decades passed, his carbonated water became popular in cities and towns...
CARLSBAD, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at JMP Securities' 4th Annual Healthcare Focus Conference on Tuesday, October 6, 2009, at 12:30 p.m. ET at the New York Palace Hotel. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the...
CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the United States Patent and Trademark Office (USPTO) has allowed an Isis patent application that further expands the scope of the "Crooke" patent estate. The newly allowed patent broadly covers methods of cleaving a target RNA via a double-stranded ribonuclease mechanism, including the RNAi mechanism, with...
CARLSBAD, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, September 14, 2009, at 1:35 p.m. ET at the Grand Hyatt New York. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of the...
CARLSBAD, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2009 Thomas Weisel Partners Healthcare Conference on Wednesday, September 9, 2009, at 11:30 a.m. ET at the Boston Four Seasons Hotel. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay of...
Fish and some amphibians possess a unique sensory capability in the so-called lateral-line system. It allows them, in effect, to "touch" objects in their surroundings without direct physical contact or to "see" in the dark. Professor Leo van Hermmen and his team in the physics department of the Technische Universities Muenchen are exploring the fundamental basis for this sensory system. What they discover might one day, through biomimetic engineering, better equip robots...
Accumulating evidence suggests that connective tissue growth factor (CCN2) plays a central role in fibrotic conditions in many organ systems. Fibrosis is a scarring condition that is characterized by excessive collagen production that impedes normal cell function and can cause organ dysfunction and failure. A hallmark of fibrosing injury in the liver is the activation of hepatic stellate cells (HSCs) which become highly proliferative, synthesize increased levels of transforming growth...
CAMBRIDGE, Mass., Aug 24 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business....
HOERSHOLM, Denmark, August 24 /PRNewswire/ -- - Santaris Pharma A/S and Shire plc to Engage in a Multi-Year Research Program Utilizing Santaris Pharma's Proprietary Locked Nucleic Acid (LNA) Drug Platform to Identify and Select Drug Candidates Against Certain Targets for the Treatment of Rare Genetic Disorders - Santaris Pharma A/S to Receive Significant Upfront Payments, Milestone Payments and Royalties for Providing Access to its LNA Technology, Exclusivity for Three...
